EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting APRIL in the treatment of glomerular diseases

Chee Kay Cheung, Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Vladimír Tesař, Hernán Trimarchi, Muh Geot Wong, Hong Zhang, Dana V Rizk

Kidney International · 2024

DOI: 10.1016/j.kint.2024.08.012 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2024. Verfasst von Chee Kay Cheung und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Heal…. Hauptthemen laut MEDLINE: Tumor Necrosis Factor Ligand Superfamily Member 13, B-Lymphocytes, Glomerulonephritis, IGA. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 99 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A proliferation-inducing ligand (APRIL) is a key member of the tumor necrosis factor superfamily of cytokines and plays a central role in B-cell survival, proliferation, and Ig class switching. Recently, there has been increasing interest in the role of APRIL and the related cytokine B-cell activating factor in several glomerular diseases, because of their importance in the above processes. The therapeutic inhibition of APRIL represents a potentially attractive immunomodulatory approach that may abrogate deleterious host immune responses in autoimmune diseases while leaving other important functions of humoral immunity intact, such as memory B-cell function and responses to vaccination, in contrast to B-cell-depleting strategies. In this review, we describe the physiological roles of APRIL in B-cell development and their relevance to glomerular diseases, and outline emerging clinical trial data studying APRIL inhibition, with a focus on IgA nephropathy where the clinical development of APRIL inhibitors is in its most advanced stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor Ligand Superfamily Member 13B-LymphocytesGlomerulonephritis, IGAHumansAnimalsKidney Glomerulus

Stichwörter der Autor:innen

APRILB cellsBAFFIgA nephropathylupus nephritismembranous nephropathy

Substanzen

Tumor Necrosis Factor Ligand Superfamily Member 13TNFSF13 protein, human

Autor:innen und Institutionen

  • Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester National Health Service Trust, Leicester, UK.
  • Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford University, Stanford, California, USA.
  • The Kidney and Transplant Practice, Mount Elizabeth Novena Hospital, Singapore.
  • Department of Nephrology, Juntendo University Faculty of Medicine, Tokyo, Japan.
  • Department of Nephrology, General University Hospital, Charles University, Prague, Czech Republic.
  • Nephrology Service and Kidney Transplant Unit, Hospital Británico de Buenos Aires, Buenos Aires, Argentina.

Zitieren

APA

Cheung, C. K., Barratt, J., Lafayette, R., Liew, A., Suzuki, Y., Tesař, V., Trimarchi, H., Wong, M. G., Zhang, H., & Rizk, D. V. (2024). Targeting APRIL in the treatment of glomerular diseases. Kidney International. https://doi.org/10.1016/j.kint.2024.08.012

Vancouver

Cheung CK, Barratt J, Lafayette R, Liew A, Suzuki Y, Tesař V, et al. Targeting APRIL in the treatment of glomerular diseases. Kidney International. 2024. doi:10.1016/j.kint.2024.08.012

BibTeX
@article{Cheung2024,
  author = {Cheung, Chee Kay and Barratt, Jonathan and Lafayette, Richard and Liew, Adrian and Suzuki, Yusuke and Tesař, Vladimír and Trimarchi, Hernán and Wong, Muh Geot and Zhang, Hong and Rizk, Dana V},
  title = {Targeting APRIL in the treatment of glomerular diseases},
  journal = {Kidney International},
  year = {2024},
  doi = {10.1016/j.kint.2024.08.012}
}
Kostenlos starten →